11 January 2019
: Case report
A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis
Challenging differential diagnosis, Diagnostic / therapeutic accidents, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Julie Fu123ABCDEF*, Lisa X. Lee14E, Ping Zhou4BCD, Teresa Fogaren1AE, Cindy Varga124E, Raymond L. Comenzo124ABCDEFGDOI: 10.12659/AJCR.912282
Am J Case Rep 2019; 20:43-47
Abstract
BACKGROUND: T-cell large granular lymphocytic leukemia (T-LGL) is a rare hematological malignancy that currently has no standard therapy. Immunoglobulin heavy chain amyloidosis (AH) involving the kidney is a rare condition and the pathology, diagnosis, clinical characteristics, and prognosis are becoming understood. This report is of a rare case of T-LGL associated with renal AH and discusses the approach to management.
CASE REPORT: A 57-year-old woman presented with symptoms of fatigue and she had proteinuria. A diagnosis of T-LGL associated with renal AH was made, which is an association that has not been previously reported in the literature. Given the dysregulation of her immune function due to her underlying T-LGL and her comorbidities, treatment options were limited. She was clinically stable and was initially observed. After one year, her symptoms of fatigue became worse, and her proteinuria increased. Treatment was initiated with the triple drug combination of bortezomib, cyclophosphamide, and dexamethasone (CyBorD) with consideration for future hematopoietic stem cell transplantation (HSCT). Her clinical condition improved, with a reduction in proteinuria.
CONCLUSIONS: A rare case of T-LGL and renal AH is presented. Currently, there is no standard therapy for T-LGL and AH amyloidosis, and the approach, in this case, was to manage the patient initially with CyBorD triple chemotherapy.
Keywords: Amyloid, Antigens, CD98 Heavy Chain, Leukemia, Large Granular Lymphocytic, Amyloidosis, Bortezomib, Cyclophosphamide, Dexamethasone, Drug Therapy, Combination, Fatigue, Glucocorticoids, Immunoglobulin Heavy Chains, Immunosuppressive Agents, Kidney Diseases, Proteinuria
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946669
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946800
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947628
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947148
Most Viewed Current Articles
21 Jun 2024 : Case report
97,828
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,727
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
32,839
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,613
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030